Yes, yes and yes, ‘nuff said @curecc @CcaEns @OHSUKnight

Molecularly Guided Therapy in Hepatobiliary Cancers: Current Standards... sciencedirect.com/science/ar… Glad to share article in Hem/Onc Clinics NA with @cofiadeva @Fen_Saj @Val_LeBleu @curecc @JaruratCare

🗞️Here it is, our latest paper on #adjuvant treatment in #BiliaryMalignancies 😬Improvement is much needed 🧐Will #IO be the answer? 🧐Shall we move to #neoadjuvant?   tandfonline.com/doi/figure/1… @Alex_MedOnc @Hospital_FJD

🌍What began as a CholangioConnect mentor-mentee match in 2022 has become a friendship spanning continents. Living thousands of miles apart in Kenya and New York, Irungu and his mentor Erica supported one another through life’s challenges. Over the years, they stayed connected through video calls, texts, family photos, and shared milestones. After several missed opportunities to meet, they finally connected in person while Irungu was in New York City for the Tribeca Film Festival, where the film he performs in was selected for screening. From brunch near Grand Central to a walk through Bryant Park, their conversation flowed as naturally as it had for years. Their story is a reminder that the connections formed through this community can grow beyond mentorship into lasting friendship. Mentorship is available for patients, caregivers, and bereaved caregivers. Please learn more and request a mentor or volunteer to be one here: curecca.org/get-one-on-one-s…

📢 Save the Date! The 8th Annual Cholangiocarcinoma Summit is coming to Grapevine, Texas, October 15–16, 2026. This is an opportunity to share data from your research studies on cholangiocarcinoma (CCA) or other biliary tract cancers with your colleagues. Please see below for the specific categories and the instructions for submitting a poster abstract for presentation during the meeting. 🗓️ Submit a Poster Abstract by Friday, August 7, 2026. 🔗 ccanewsonline.com/summit/pos…

Are you balancing work & cancer? Get tips, tools & more at the @CancerAndCareer virtual National Conference on Work & Cancer. Register today! cancerandcareers.org/confere… #CACconf

Join our upcoming Webinar: A trial of next-generation immunotherapy (Rilvegostomig) plus chemotherapy in advanced biliary tract cancer (ARTEMIDE-Biliary02) on June 16, 2026, at 4:00 p.m. ET with Dr. Lipika Goyal. Patients with newly diagnosed advanced biliary tract cancer are often treated with immunotherapy plus chemotherapy. This webinar will discuss a new ongoing clinical trial in biliary tract cancer investigating a new immunotherapy drug called rilvegostomig in combination with standard chemotherapy. The study called ARTEMIDE-Biliary02 is a phase III randomized global study of rilvegostomig or durvalumab in combination with chemotherapy in first-line treatment of advanced biliary tract cancer.  This webinar is sponsored by AstraZeneca. Register today at curecca.link/june16th.

The 2026 Los Angeles Cholangiocarcinoma Symposium is set to convene in Los Angeles, drawing together leading experts, researchers, healthcare professionals, patients, and advocates. This event promises to be a crucial platform for sharing the latest advancements and addressing the challenges in cholangiocarcinoma research and treatment. 🗓️ September 19, 2026 ⏱️ 8:00am – 4:00pm 📍University of Southern California Snacks, Beverages, and Lunch will be served Register today at curecca.link/la2026.

Patients often receive biomarker test results without fully understanding what they mean. This free webinar will help explain common testing terms, reports, and an AI tool to understand results.    📅 June 15  🔗 Register here: shorturl.at/0PGJU    #BiomarkerTesting #PrecisionMedicine #CancerCare

🌟 Today, on National Cancer Survivors Day, we celebrate the incredible strength and resilience of cholangiocarcinoma patients and survivors. Your journey is a testament to the power of community and the hope that research brings. With every step forward, we embrace our motto, "Strength in Community, Hope in Research." Together, we support one another, fuel advancements, and foster a future where hope shines brighter than ever. Thank you for your courage and determination. You inspire us all. 💪🏼💚

🆕@JCOPO_ASCO 💡Such a beautiful story of real world🌎 precision medicine. Meet➡️#ERRFI1🎯 📝Time to add➕this to ACTIONABLE Biomarkers🔐for #cholanagiocarcinoma @curecc. @NCCN 👇🏽Patient in paper, I took off hospice to give Erlotinib💊. @OncoAlert 🔗ascopubs.org/doi/10.1200/PO-…

CCF’s new CholangioPath app empowers patients to connect with a Patient Advocate, explore treatment information, receive reminders about educational events, and access new resources, making it easier to stay informed and supported throughout your journey. Learn more and download the CholangioPAth app today at curecca.org/app. Thank you to our founding sponsors, Jazz Pharmaceuticals, Taiho Oncology, Incyte, and Compass Therapeutics for making this resource possible.

Biomarker test reports can include complex terms and unfamiliar information. This free webinar will help patients and caregivers better understand biomarker testing results and how to use an AI tool to understand results. 📅 June 15 Register here: shorturl.at/0PGJU .

ascopubs.org/doi/full/10.120… Some stories are so meaningful @https://www.cholangio.ca/cycle/cynthia. Drug availability in oncology is a major limitation. @mcuban and his @costplusdrugs made it possible for many to get access to this EGFR inhibitor @curecc @MiteshBorad

📢 Save the Date! The 8th Annual Cholangiocarcinoma Summit is coming to Grapevine, Texas, October 15–16, 2026. Researchers and clinicians are invited to share their work by submitting a poster abstract for this year’s Summit. This is an opportunity to showcase the latest advances in cholangiocarcinoma research and connect with leaders across the field. 🗓️ Submit a Poster Abstract by Friday, August 7, 2026. 🔗 ccanewsonline.com/summit/pos…

@ASCO Abstract 3008: #DrlingjunZhu presented data on targeting KRAS G12D in CCA with GFH375: N=20; 75% in 3L , ORR 40%, Med PFS 6.2 mo, OS not reached. Direction of future research in CCA @curecc @CharityAMMF @MCRCnews GI toxicities, cytopenias AEs.

RT @curecc: Twenty years ago, a cholangiocarcinoma diagnosis often came with more questions than answers. There were few treatment options,…

Congratulation to the KRAS Pancreatic community. Coming soon to the KRAS CCA community 💚

📢 Join us for the 2026 Cleveland Cholangiocarcinoma Symposium! On June 26, 2026, leading experts, researchers, healthcare professionals, patients, and advocates will gather in Cleveland for an important day dedicated to advancing cholangiocarcinoma research, treatment, and patient care. We are honored to welcome @DrHaleyEllis as our keynote speaker. 🗓 Date: June 26, 2026 🕚 Time: 11:00 AM – 4:30 PM 📍 Location: Cleveland Clinic, Taussig Cancer Institute (Building CA) This symposium will serve as a vital platform for collaboration, education, and innovation as we work together to address the challenges of cholangiocarcinoma. ✅ Register today at curecca.link/cleveland.

@GIcancerDoc presents phase 3 #FIGHT-302 study of #pemigatinib in patients with #CCA with #FGFR2 gene fusion at #ASCO26 @ASCO @JCO_ASCO @curecc @CharityAMMF @atuvibi @VoiesBiliaires #APIC @CcaEns @PrecisionBTCnet